NCT04737967

The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Mendel AI · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a double blinded two-arm randomized case-only interventional trial. A total of 60 patients who are to receive Paclitaxel to be included and allocated in two groups. The protocol is to be reviewed by the Research Ethics Committee of Faculty of Medicine Cairo University. All procedure will be done in Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine. The first arm (Venlafaxine group) will receive Venlafaxine extended release (37.5 mg) tablets (Zimmerman et al., 2016). The second arm (Memantine group) will receive memantine 10 mg once daily (Morel et al., 2016)

Conditions

• Oncology Pain
• Chemotherapy-induced Peripheral Neuropathy

Interventions

Type	Name	Description
DRUG	Venlafaxine	Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)
DRUG	Memantine	Patients will receive memantine (10 mg) once daily (Morel et al., 2016)

Timeline

• Start date: 2021-02-15
• Primary completion: 2021-08-15
• Completion: 2021-10-01
• First posted: 2021-02-04
• Last updated: 2021-02-04

Locations

1 site across 1 country: Egypt